Dopaminect Tablet

Brand Name:  Dopaminect 1 mg Tablet
Active Ingredient: Rasagiline Mesylate    

When is Dopaminect Tablet prescribed for?
DOPAMINECT is indicated for the treatment of idiopathic Parkinson's disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
 

How should you take Dopaminect Tablet?

The recommended Dopaminect dose as monotherapy for the treatment of Parkinson’s disease patients is 1 mg administered orally once daily.
The recommended initial dose of Dopaminect as adjunctive therapy is 0.5 mg administered orally once daily. 
If a sufficient clinical response is not achieved, the dose may be increased to 1 mg administered once daily.
 

When you should not take Dopaminect Tablet?

  • Hypersensitivity to the active substance or to any of the excipients
  • Concomitant treatment with other monoamine oxidase (MAO) inhibitors (including medicinal and natural products without prescription e.g. St. John's Wort) or pethidine At least 14 days must elapse between discontinuation of rasagiline and initiation of treatment with MAO inhibitors or pethidine.
  • Rasagiline is contraindicated in patients with severe hepatic impairment.
     

Possible Drug interaction with Dopaminect Tablet:

  • Rasagiline must not be administered along with other MAO inhibitors (including medicinal and natural products without prescription e.g. St John's Wort) as there may be a risk of non-selective MAO inhibition that may lead to hypertensive crises
  • The concomitant administration of rasagiline and pethidine is contraindicated.
  • Concomitant administration of rasagiline and sympathomimetics such as those present in nasal and oral decongestants or cold medicinal products, containing ephedrine or pseudoephedrine, is not recommended.
  • The concomitant administration of rasagiline and dextromethorphan is not recommended.
  • The concomitant use of rasagiline and fluoxetine or fluvoxamine should be avoided.
  • Potent CYP1A2 inhibitors may alter rasagiline plasma levels and should be administered with caution.
  • Concomitant administration of rasagiline and entacapone increased rasagiline oral clearance by 28%.
     

Special warning and precaution on using Dopaminect Tablet:

  • The concomitant use of rasagiline and fluoxetine or fluvoxamine should be avoided at least five weeks should elapse between discontinuation of fluoxetine and initiation of treatment with rasagiline At least 14 days should elapse between discontinuation of rasagiline and initiation of treatment with fluoxetine or fluvoxamine.
  • Impulse control disorders (ICDs) can occur in patients treated with dopamine agonists and/or dopaminergic treatments.
  • There have been reports of hypotensive effects when rasagiline is taken concomitantly with levodopa.
  • The concomitant use of rasagiline and dextromethorphan or sympathomimetics such as those present in nasal and oral decongestants or cold medicinal product containing ephedrine or pseudoephedrine is not recommended.
  • The occurrence of cases of melanoma prompted the consideration of a possible association with rasagiline.
  • Caution should be used when initiating treatment with rasagiline in patients with mild hepatic impairment. Rasagiline use in patients with moderate hepatic impairment should be avoided.
     

Special information if you are pregnant or breastfeeding

  • For rasagiline no clinical data on exposed pregnancies is available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. Caution should be exercised when prescribing to pregnant women.
  • Experimental data indicated that rasagiline inhibits prolactin secretion and, thus, may inhibit lactation.
    It is not known whether rasagiline is excreted in human milk. Caution should be exercised when rasagiline is administered to a breast-feeding mother.
     

Possible Side Effects with Dopaminect Tablet:

  • Serious adverse reactions are known to occur with concomitant use of SSRIs, SNRIs, tricyclic, tetracyclic antidepressants and MAO inhibitors. In the post-marketing period, cases of serotonin syndrome associated with agitation, confusion, rigidity, pyrexia and myoclonus have been reported by patients treated with antidepressants/SNRI concomitantly with rasagiline.
  • In the post-marketing period, cases of elevated blood pressure, including rare cases of hypertensive crisis associated with ingestion of unknown amounts of tyramine-rich foods, have been reported in patients taking rasagiline.
  • Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments